148 related articles for article (PubMed ID: 3978558)
1. Low-dose cytosine arabinoside treatment for acute nonlymphocytic leukemia in elderly patients.
Tilly H; Castaigne S; Bordessoule D; Sigaux F; Daniel MT; Monconduit M; Degos L
Cancer; 1985 Apr; 55(8):1633-6. PubMed ID: 3978558
[TBL] [Abstract][Full Text] [Related]
2. High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukemia: a Leukemia Intergroup Study.
Preisler HD; Raza A; Barcos M; Azarnia N; Larson R; Walker I; Browman M; Grunwald H; D'Arrigo P; Doeblin T
J Clin Oncol; 1987 Jan; 5(1):75-82. PubMed ID: 3806162
[TBL] [Abstract][Full Text] [Related]
3. Low-dose cytosine arabinoside for treating hypocellular acute leukemia in the elderly.
Kanamori H; Maruta A; Miyashita H; Harano H; Fukawa H; Matsuzaki M; Motomura S; Mohri H; Kodama F; Okubo T
Am J Hematol; 1992 Jan; 39(1):52-5. PubMed ID: 1536140
[TBL] [Abstract][Full Text] [Related]
4. Small-dose cytosine arabinoside in the treatment of elderly patients with acute leukemia and refractory anemia with excess of blast.
Satou Y; Kubota T; Yonekura S; Noguchi K; Oobayashi Y; Nagao T; Arimori S
Tokai J Exp Clin Med; 1986 Oct; 11(4):249-54. PubMed ID: 3617109
[TBL] [Abstract][Full Text] [Related]
5. High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia.
Hines JD; Oken MM; Mazza JJ; Keller AM; Streeter RR; Glick JH
J Clin Oncol; 1984 Jun; 2(6):545-9. PubMed ID: 6233399
[TBL] [Abstract][Full Text] [Related]
6. An attempt at synchronization of marrow cells in acute leukemia: relationship to therapeutic response.
Kremer WB; Vogler WR; Chan YK
Cancer; 1976 Jan; 37(1):390-403. PubMed ID: 1082365
[TBL] [Abstract][Full Text] [Related]
7. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia.
Herzig RH; Lazarus HM; Wolff SN; Phillips GL; Herzig GP
J Clin Oncol; 1985 Jul; 3(7):992-7. PubMed ID: 3894588
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.
Tallman MS; Appelbaum FR; Amos D; Goldberg RS; Livingston RB; Mortimer J; Weiden PL; Thomas ED
J Clin Oncol; 1987 Jun; 5(6):918-26. PubMed ID: 3585446
[TBL] [Abstract][Full Text] [Related]
9. High-dose cytosine arabinoside, daunomycin and 6-thioguanine in relapsed or refractory acute nonlymphocytic leukemia.
Garewal H; Durie BG; Greenberg B
Oncology; 1987; 44(6):333-5. PubMed ID: 3684173
[TBL] [Abstract][Full Text] [Related]
10. Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia.
Winter JN; Variakojis D; Gaynor ER; Larson RA; Miller KB
Cancer; 1985 Aug; 56(3):443-9. PubMed ID: 3859362
[TBL] [Abstract][Full Text] [Related]
11. Limited efficacy of a four-day course of high-dose cytosine arabinoside in the treatment of poor-risk patients with acute nonlymphocytic leukemia.
Preisler HD; Raza A; Larson R; Browman G; Goldberg J; Grunwald H; Vogler R; Bennett J; Gottlieb A; D'Arrigo P
Cancer Chemother Pharmacol; 1986; 18(3):257-60. PubMed ID: 3802381
[TBL] [Abstract][Full Text] [Related]
12. Randomized clinical trial of cystosine arabinoside and 6-thioguanine in remission induction and consolidation of adult nonlymphocytic acute leukemia.
Lewis JP; Linman JW; Marshall GJ; Pajak TF; Bateman JR
Cancer; 1977 Apr; 39(4):1387-96. PubMed ID: 322835
[TBL] [Abstract][Full Text] [Related]
13. Prediction of response of acute nonlymphocytic leukaemia to therapy with 'high dose' cytosine arabinoside.
Preisler HD; Epstein J; Barcos M; Priore R; Raza A; Browman GP; Vogler R; Winton E; Grunwald H; Rai K
Br J Haematol; 1984 Sep; 58(1):19-32. PubMed ID: 6466567
[TBL] [Abstract][Full Text] [Related]
14. Treatment of "poor risk" acute nonlymphocytic leukemia with continuously infused low-dose cytosine arabinoside.
Balaban EP; Cox JV; Schneider NR; Harth CA; Haley BB; Sheehan R; Frenkel EP
Am J Hematol; 1988 Oct; 29(2):79-84. PubMed ID: 3189306
[TBL] [Abstract][Full Text] [Related]
15. [Value of high-dose cytosine-arabinoside in the treatment of resistant acute leukemia].
Witz F; Olive D; Lederlin P; Bordigoni P; Troussard X; Grosbois B; Schaison G; Cornu G
Presse Med; 1987 Feb; 16(4):159-62. PubMed ID: 2950446
[TBL] [Abstract][Full Text] [Related]
16. [High-dose cytosine arabinoside treatment of leukemia with special reference to the optimal number of doses].
Sampi K; Maseki N; Kumai R; Kaneko Y; Sakurai M; Hattori M
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2595-8. PubMed ID: 2774589
[TBL] [Abstract][Full Text] [Related]
17. Treatment of refractory leukemia with high-dose cytosine arabinoside.
Klener P; Háber J
Neoplasma; 1985; 32(1):113-7. PubMed ID: 3856754
[TBL] [Abstract][Full Text] [Related]
18. High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia.
Chan HY; Meyers FJ; Lewis JP
Cancer Chemother Pharmacol; 1987; 20(3):265-6. PubMed ID: 3677301
[TBL] [Abstract][Full Text] [Related]
19. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update.
Wolff SN; Herzig RH; Phillips GL; Lazarus HM; Greer JP; Stein RS; Ray WA; Herzig GP
Semin Oncol; 1987 Jun; 14(2 Suppl 1):12-7. PubMed ID: 3589687
[TBL] [Abstract][Full Text] [Related]
20. Relationship between the per cent of marrow cells in S phase and the outcome of remission-induction therapy for acute nonlymphocytic leukaemia.
Preisler HD; Azarnia N; Raza A; Grunwald H; Vogler R; Browman G; Goldberg J; Chervenick P; Miller K; Brennan J
Br J Haematol; 1984 Mar; 56(3):399-407. PubMed ID: 6582925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
